Last $24.56 USD
Change Today -0.91 / -3.57%
Volume 212.2K
RGEN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Open
$25.50
Previous Close
$25.47
Day High
$25.50
Day Low
$24.40
52 Week High
10/31/14 - $26.75
52 Week Low
03/27/14 - $12.04
Market Cap
803.6M
Average Volume 10 Days
295.7K
EPS TTM
$0.36
Shares Outstanding
32.7M
EX-Date
--
P/E TM
68.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yields during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

116 Employees
Last Reported Date: 03/14/14
Founded in 1981

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $475.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.0K
Vice President of Business Development
Total Annual Compensation: $262.5K
Senior Advisor
Total Annual Compensation: $272.5K
Compensation as of Fiscal Year 2013.

repligen corp (RGEN) Key Developments

Repligen Corporation Announces Executive Changes, Effective May 21, 2015

Repligen Corporation announced that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders. Prior to his role as COO at Repligen, Mr. Hunt was President, BioProduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed in February 2014. Mr. Hunt joined Life Technologies in 2008, as General Manager Bioproduction Chromatography and Pharma Analytics and played a key role in the development and growth of the company's bioprocessing business.

Repligen Reports Preliminary Unaudited Revenue Results for the Fiscal Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Repligen reported preliminary unaudited revenue results for the fiscal year ended December 31, 2014. For the period, the company reported total revenue of $63-$63.5 million. This total revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic programs and product revenue of $60-$60.5 million, an increase from previous product revenue guidance of $58-$60 million. Product revenue reflects sales growth of 26%-27%, driven by strength in sales of products that the company sells directly to end users including partial year sales of the Alternating Tangential Flow System (the ATF System), the most recent addition to Repligen's proprietary product portfolio. For 2015, the company currently projects product revenue in the range of $69-$72 million, reflecting 15%-20% sales growth compared to 2014, which included only partial year sales of the ATF System. Gross margin on product sales is expected to be greater than 55% in 2015. These projections do not include the impact on product revenue or gross margin of potential acquisitions and/or fluctuations in currency exchange rates during 2015.

Repligen Corporation Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

Repligen Corporation reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue was $15,278,185,000 against $18,822,053,000 a year ago. Income from operations was $2,216,230,000 against $8,041,759,000 a year ago. Income before income taxes was $2,254,552,000 against $8,142,779,000 a year ago. Net income was $1,466,236,000 or $0.04 diluted per share against $5,888,274,000 or $0.18 diluted per share a year ago. Operating income for the quarter was $2.2 million. For the six months, the company reported total revenue was $47,155,116,000 against $52,787,013,000 a year ago. Income from operations was $10,629,928,000 against $17,689,521,000 a year ago. Income before income taxes was $10,895,904,000 against $17,798,550,000 a year ago. Net income was $8,568,759,000 or $0.26 diluted per share against $12,765,697,000 or $0.40 diluted per share a year ago. The company generated positive cash flow of $11.5 million to partially offset the $21.2 million used for the Refine Technology acquisition. The company revises its earnings guidance for the year 2014. Total revenues are expected to be $60 million-$62 million, an adjustment to previous guidance of $59 million-$62 million. Total product revenue for 2014 is expected to be $58-$60 million, an increase from previous guidance of $57-$60 million. This reflects annual growth of 22%-26%. Effective tax rate is expected to be 21%-23% of pretax income, a decrease from previous guidance of 23%-25%. Total income from operations is expected to be $11 million-$13 million. Total net income projection is $8 million-$10 million. The company expected tax rate of 21% to 23%. Capital expenditures are expected to be approximately $6 million, which includes $4 million to expand Waltham, Massachusetts facility to accommodate ATF system manufacturing and $2 million to maintain existing facilities and equipment. Based on the aforementioned projections, expecting year-end cash of $64 million to $68 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $24.56 USD -0.91

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $61.33 USD -0.66
View Industry Companies
 

Industry Analysis

RGEN

Industry Average

Valuation RGEN Industry Range
Price/Earnings 70.7x
Price/Sales 13.3x
Price/Book 7.3x
Price/Cash Flow 70.1x
TEV/Sales 12.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit www.repligen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.